Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-17.0,  Dravet Syndrome Clinical diagnosis of Dravet Syndrome. Participants must have seizures which are not completely controlled by anti-epileptic drugs (AEDs) with the following Onset of frequent seizures prior to 18 months of age Normal development at onset History of seizures that are generalized, unilateral clonic, and/or hemi-clonic, namely Hemi-clonic (Note: Lateralization right body, left body, or independent R and L) Focal with clear, observable motor signs (i.e., automatisms, dystonic posturing, focal tonic stiffening) Secondarily generalized tonic clonic (evolving to bilateral convulsive seizure from focal seizure) Generalized tonic clonic convulsion Tonic   The Independent Reviewer will confirm Dravet Syndrome diagnosis for each participant enrolled in the study. 3. Seizure of ≥4 countable convulsive seizures (tonic-clonic, tonic, clonic, atonic, focal with observable motor signs) per 4-week baseline period (Observational Phase). 4. Participants should be on a stable regimen of AEDs≥30days prior to Visit 1 and generally in good health. 5. Parent or Legal Authorised Representative (LAR) is willing and able to maintain an accurate and complete daily seizure calendar. 6. Sexually active women of child-bearing potential (WCBP) must be using a medically acceptable method of birth control and have a negative urine pregnancy test at the screening visit. A WCBP is defined as a female who is biologically capable of becoming pregnant. A medically acceptable method of birth control includes intrauterine devices in place for at least 3 months, surgical sterilization, or adequate barrier methods (e.g., diaphragm and foam). Use of oral contraceptives in combination with another method (e.g., a spermicidal cream) is acceptable. In participants who are not sexually active, abstinence is an acceptable form of birth control and urine will be tested per protocol. Women who are of non-child-bearing potential, i.e., post-menopause, must have this condition captured in their medical history. Pregnant women are excluded from this study. 7. Have parent or LAR available and willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures The presence of any of the following excludes a participant from study enrollment: 1. Known sensitivity, allergy, or previous exposure to EPX-100 (clemizole HCl). 2. Exposure to any investigational drug or device <90 days prior to screening or plans to participate in another drug or device trial at any time during the study. 3. Seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or central nervous system (CNS) disease deemed progressive, metabolic illness, or progressive degenerative disease. 4. Concurrent use of drugs known to interfere with EPX-100, including moderate or severe inducers or inhibitors of CYP3A4/5/7. Specifically, concurrent use of carbamazepine, oxcarbazepine, phenytoin, and/or phenobarbital, or fenfluramine as an investigational drug, are excluded, as well as refraining from grapefruits and grapefruit juice during the study period. 5. Has any medical condition that, in the PI's judgement, is considered to be clinically significant and could potentially affect participant safety or study outcome, including but not limited to: clinically significant cardiac disease (including angina, congestive heart failure, uncontrolled hypertension, and history of arrhythmias), renal, pulmonary, gastrointestinal, hematologic or hepatic conditions; or a condition that affects the absorption, distribution, metabolism, or excretion of drugs. 6. Has an active suicidal plan/intent or have had active suicidal thoughts in the past 6 months or a suicide attempt in the past 3 years